When was WuXi Biologics founded?

WuXi Biologics was founded in 2008.

Where is WuXi Biologics located?

WuXi Biologics is headquartered in Shanghai, China.

How many employees does WuXi Biologics have?

As of Aug 31, 2026, the latest employee count at WuXi Biologics is 3082.

Where does WuXi Biologics rank among its competitors?

WuXi Biologics ranks 12th amongst 370 active competitors, of which 41 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Biofortuna, which secured $303K in Feb, 2026.

Who are the top competitors of WuXi Biologics?

WuXi Biologics' top competitors include Novartis, Catalent and Biotage. Among them, Biofortuna secured the most recent funding round in February, 2026.

WuXi Biologics - 2026 Company Profile, Team, Funding & Competitors

WuXi Biologics is a public company based in Shanghai (China), founded in 2008. It operates as a Developer and manufacturer for protein therapeutics. The company has 370 active competitors, including 41 funded and 53 that have exited. Its top competitors include companies like Novartis, Catalent and Biotage.

Company Details

In 2022, the company recorded annual revenues of $2.27B and a net profit of $0.66B

Website: www.wuxibiologics.com/
Social
Part Of

Key Metrics

Founded Year

2008

Location

Shanghai, China

Stage

Public

Investors

Temasek & 4 more

Ranked

12^th among 370 active competitors

Employee Count

3,082 as on Aug 31, 2026

Investment & Acquisitions

Immune-Onc Therapeutics & 7 more

Similar Companies

Novartis & 422 more

Exit Details

Public

View WuXi Biologics' full profile

WuXi Biologics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
WUXI BIOLOGICS USA LLC CIN: 812371818 , United States, Active	Dec 31, 1999	-	388 (As on Dec 31, 2024)	-

WuXi Biologics got listed on Jun 13, 2017.

Click here to take a look at WuXi Biologics's IPO in detail

WuXi Biologics is a funded company. WuXi Biologics has 5 institutional investors.

View details of WuXi Biologics's funding rounds and investors

WuXi Biologics' employee count trend

WuXi Biologics has 3,082 employees as of Aug 26. Here is WuXi Biologics's employee count trend over the years:

Uncover WuXi Biologics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of WuXi Biologics include Novartis, Catalent and Biotage. Here is the list of Top 10 competitors of WuXi Biologics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, Genstar Capital & 4 others	68/100
3rd	Biotage 1989, Uppsala (Sweden), Acquired	Organic synthesis, analytical, and peptide chemistry services for drug discovery and development	-	Taaleri, Investor Growth Capital & 4 others	63/100
4th	Surrozen 2016, San Francisco (United States), Public	Pioneering targeted regenerative antibodies to repair tissue and restore organ function	$133M	The Column Group, Horizons Ventures & 13 others	59/100
5th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	56/100
6th	Biofortuna 2008, Birkenhead (United Kingdom), Series A	Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services	$21.6M	Foresight Group, Gov Wales & 12 others	55/100
7th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	Cencora, Alabama Launchpad & 7 others	55/100
8th	Stelis Biosource 2012, Bengaluru (India), Series C	CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs	$195M	TPG, Think Investments & 3 others	53/100
9th	AmplifyBio 2021, Hilliard (United States), Deadpooled	Provider of contract research, development, and manufacturing services for biologic drugs	$230M	Hercules Capital, Casdin Capital	53/100
10th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100
12th	WuXi Biologics 2008, Shanghai (China), Public	Developer and manufacturer for protein therapeutics	-	Temasek, Osmium Global & 3 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on WuXi Biologics's competitors? Click here to see the top ones

WuXi Biologics has made 7 investments in companies including Immune-Onc Therapeutics and Adlai Nortye. WuXi Biologics has also acquired 1 companies including CMAB Biopharma.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 05, 2023	Investments	Immune-Onc Therapeutics	2016	Palo Alto (United States)
Jul 15, 2021	Investments	Adlai Nortye	2014	Hangzhou (China)
Mar 30, 2021	Investments	Immune-Onc Therapeutics	2016	Palo Alto (United States)